Evkeeza® (evinacumab-dgnb) – Expanded indication
March 22, 2023 - Regeneron Pharmaceuticals announced the FDA approval of Evkeeza (evinacumab-dgnb), as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia (HoFH).
Top